Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 7 | BMC Cancer

Fig. 7

From: Integrated multi-omics reveal lactate metabolism-related gene signatures and PYGL in predicting HNSCC prognosis and immunotherapy efficacy

Fig. 7

PYGL expression and survival Analyses. (A) By Ranger and SWSFS algorithm, PYGL was identified as the most important hub gene in the risk signature. (B) PYGL expression in paired 44 paracancerous and tumor tissues from the TCGA cohort. (C) PYGL protein expression in tumor and normal samples in the CPTAC cohort. (D-E) IHC staining images and PYGL protein levels in adjoining non-tumor tissue and OC tissue. (F) Kaplan-Meier curves of OS for PYGL in the TCGA and GEO cohorts. (G) The association of the PYGL expression with the clinical T stage. (H) Analyses of correlation between PYGL and lactylation level. (I) Analyses of correlation between PYGL and six energy metabolism score. (J) Wb was performed to detect the efficiency of PYGL-shRNA transfection. (K) Lactate concentration was detected in medium supernatant after transfection with PYGL shRNA for 48 h. (L-M) PYGL and LDHA mRNA expression in SCC7 cells exposed to hypoxia for 0–24 h examined by qRT-PCR. (N) HIF1A and PYGL protein expression in SCC7 cells 0–24 h examined by western blotting

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us